Intravenous immunoglobulin G: Trends in production methods, quality control and quality assurance

M. Radosevich, T. Burnouf

研究成果: 雜誌貢獻回顧型文獻

90 引文 (Scopus)

摘要

Intravenous immunoglobulin G (IVIG) is now the leading product obtained by fractionation of human plasma. It is the standard replacement therapy in primary and acquired humoral deficiency, and is also used for immunomodulatory therapy in various autoimmune disorders and transplantation. Over the last 30 years, the production processes of IVIG have evolved dramatically, gradually resulting in the development of intact IgG preparations safe to administer intravenously, with normal half-life and effector functions, prepared at increased yield, and exhibiting higher pathogen safety. This article reviews the developments that have led to modern IVIG preparations, the current methods used for plasma collection and fractionation, the safety measures implemented to minimize the risks of pathogen transmission and the major quality control tests that are available for product development and as part of mandatory batch release procedures.
原文英語
頁(從 - 到)12-28
頁數17
期刊Vox Sanguinis
98
發行號1
DOIs
出版狀態已發佈 - 一月 2010
對外發佈Yes

指紋

Intravenous Immunoglobulins
Quality Control
Immunoglobulin G
Safety
Infectious Disease Transmission
Immunomodulation
Half-Life
Transplantation
Therapeutics

ASJC Scopus subject areas

  • Hematology

引用此文

Intravenous immunoglobulin G : Trends in production methods, quality control and quality assurance. / Radosevich, M.; Burnouf, T.

於: Vox Sanguinis, 卷 98, 編號 1, 01.2010, p. 12-28.

研究成果: 雜誌貢獻回顧型文獻

@article{22a7d4b636da481284e28643d5a1b952,
title = "Intravenous immunoglobulin G: Trends in production methods, quality control and quality assurance",
abstract = "Intravenous immunoglobulin G (IVIG) is now the leading product obtained by fractionation of human plasma. It is the standard replacement therapy in primary and acquired humoral deficiency, and is also used for immunomodulatory therapy in various autoimmune disorders and transplantation. Over the last 30 years, the production processes of IVIG have evolved dramatically, gradually resulting in the development of intact IgG preparations safe to administer intravenously, with normal half-life and effector functions, prepared at increased yield, and exhibiting higher pathogen safety. This article reviews the developments that have led to modern IVIG preparations, the current methods used for plasma collection and fractionation, the safety measures implemented to minimize the risks of pathogen transmission and the major quality control tests that are available for product development and as part of mandatory batch release procedures.",
keywords = "Fractionation, Human plasma, Immunoglobulin G, IVIG, Quality control, Standards, Viral safety",
author = "M. Radosevich and T. Burnouf",
year = "2010",
month = "1",
doi = "10.1111/j.1423-0410.2009.01226.x",
language = "English",
volume = "98",
pages = "12--28",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Intravenous immunoglobulin G

T2 - Trends in production methods, quality control and quality assurance

AU - Radosevich, M.

AU - Burnouf, T.

PY - 2010/1

Y1 - 2010/1

N2 - Intravenous immunoglobulin G (IVIG) is now the leading product obtained by fractionation of human plasma. It is the standard replacement therapy in primary and acquired humoral deficiency, and is also used for immunomodulatory therapy in various autoimmune disorders and transplantation. Over the last 30 years, the production processes of IVIG have evolved dramatically, gradually resulting in the development of intact IgG preparations safe to administer intravenously, with normal half-life and effector functions, prepared at increased yield, and exhibiting higher pathogen safety. This article reviews the developments that have led to modern IVIG preparations, the current methods used for plasma collection and fractionation, the safety measures implemented to minimize the risks of pathogen transmission and the major quality control tests that are available for product development and as part of mandatory batch release procedures.

AB - Intravenous immunoglobulin G (IVIG) is now the leading product obtained by fractionation of human plasma. It is the standard replacement therapy in primary and acquired humoral deficiency, and is also used for immunomodulatory therapy in various autoimmune disorders and transplantation. Over the last 30 years, the production processes of IVIG have evolved dramatically, gradually resulting in the development of intact IgG preparations safe to administer intravenously, with normal half-life and effector functions, prepared at increased yield, and exhibiting higher pathogen safety. This article reviews the developments that have led to modern IVIG preparations, the current methods used for plasma collection and fractionation, the safety measures implemented to minimize the risks of pathogen transmission and the major quality control tests that are available for product development and as part of mandatory batch release procedures.

KW - Fractionation

KW - Human plasma

KW - Immunoglobulin G

KW - IVIG

KW - Quality control

KW - Standards

KW - Viral safety

UR - http://www.scopus.com/inward/record.url?scp=73649119908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73649119908&partnerID=8YFLogxK

U2 - 10.1111/j.1423-0410.2009.01226.x

DO - 10.1111/j.1423-0410.2009.01226.x

M3 - Review article

C2 - 19660029

AN - SCOPUS:73649119908

VL - 98

SP - 12

EP - 28

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

IS - 1

ER -